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ABSTRACT

Trophoblast cells migrate from the placenta into the endocervical canal early in
the first trimester and can be collected non-invasively by transcervical sampling
(TCS), potentially providing fetal DNA for prenatal genetic diagnosis.
Experiments were conducted to separate fetal cells from maternal cells within the
TCS specimens and use the fetal cells to perform genetic analysis. Trophoblast
cells were efficiently isolated from TCS specimens during weeks 5-18 of
gestation

using

HLA-G

antibody

coupled

to

magnetic

nanoparticles.

Immunofluorescence microscopy revealed that 99% of isolated cells expressed
the chorionic gonadotropin β subunit (β-CG), while the non-bound cell fraction
expressed none. Immunomagnetically isolated cells from 20 patient specimens
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were used to determine fetal gender in single cell assays, amplifying sequences
in genes on the X (DMD) and Y (SRY) chromosomes by multiplex polymerase
chain reaction (PCR). Of 270 total cells, PCR products were detected in 256
cells and identified gender (11 male; 9 female) without error. PCR-based genetic
testing is highly reliable as early as week 5 of gestation after immunomagnetic
isolation of extravillous trophoblast cells obtained by TCS.

INTRODUCTION

Prenatal genetic diagnosis is an appropriate course of action to take in a
pregnancy when it is known that one of the biological parents has a genetically
inheritable disease or when the biological mother’s age is so advanced that it
may introduce genetic abnormalities to the embryo. In fact, there is a 3% to 5%
chance that an infant will be born with a chromosomal abnormality or a structural
defect (O’Leary et al., 2006). Yet, as of now, there are many limitations as to
how genetic testing can take place. The earliest that genetic testing can be done
is in the first trimester after 10 to 12 weeks of pregnancy using chorionic villus
sampling (CVS). It is not the most reliable method, and it puts the woman at risk
for infection or a 2% chance of miscarriage (Mujezinovic and Alfirevic, 2007).
There is also evidence that CVS can cause preeclampsia, a condition some
pregnant women develop in which their blood pressure increases and excess
protein is found in their urine (Silver et al., 2005). Preeclampsia can be fatal to
both the mother and the baby, and it typically necessitates an early delivery with
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prematurity. An alternative method to CVS is amniocentesis. Amniocentesis can
only be performed in the second trimester between the woman’s 15th and 20th
week of pregnancy. It is also an invasive method that puts the pregnancy at a
1.9% chance of miscarriage (Mujezinovic and Alfirevic, 2007).

Operator

experience is a major factor in safety (Wapner, 2005), and the risk of pregnancy
loss is usually less than 1% with an experienced physician.

Through this research project, an alternative method for prenatal genetic
diagnosis was explored. This method is based on a non-invasive method that
can be performed earlier on in the pregnancy (Imudia et al., 2009). Cervical
specimens similar to those collected for a PAP smear contain mostly cells shed
from the endocervical canal.

However, during weeks 6-14 of pregnancy,

trophoblast cells migrating from the placenta reside in the cervix and can be
identified by their expression of embryo-specific proteins, including HLAG
(Imudia et al., 2010).

Time was taken to develop an isolation technique for

separating HLAG positive cells from HLAG negative cells using a trophoblast cell
line capable of HLAG expression.

The method developed uses specific

antibodies bound to magnetic nanoparticles to isolate the trophoblast cells, which
have now been successfully isolated them from actual cervical specimens for
genetic testing of the fetus. This provides the mother with an earlier time frame
to decide how to handle her pregnancy if an embryonic genetic or chromosomal
abnormality does show up. It will also eliminate the risk of miscarriage, as it is a
non-invasive technique.
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These experiments were proposed to demonstrate proof-of-principle that
isolation of trophoblast cells is indeed possible when combined with an excess of
different cells to simulate a cervical sample and that single-cell methodology can
be used to assess the purity and fetal origin of isolated trophoblast cells by DNA
fingerprinting.

Initially, a human trophoblast cell line (HTR) was used to isolate cells expressing
an embryo-specific protein from a solution containing an excess of cells that lack
the protein.

Once this method was developed, multiple cervical samples

collected from clinics that our lab collaborates with were used to demonstrate
that the method is feasible using actual cervical samples. Once the cervical
samples were collected from patients in the clinics, the samples were fixed in the
lab using Methanol Acetic Acid to prevent the cells from changing between the
time samples were received and the time that they were tested. After the cells
were fixed, they were separated based on their expression of HLAG. The cells
were incubated with magnetic beads that have HLAG antibody coupled to their
surface. Thus, all of the HLAG positive cells became bound to the magnetic
beads, and the HLAG negative cells remained free of beads. The cell mixture
was then magnetized, the idea being that all of the bead-bound cells should be
attracted towards the magnet.

Discarding the supernatant and sufficiently

washing the cells bound to the magnet obtained a pure sample of HLAG positive
cells. This method was tested using cultured trophoblast cells that were forced to
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express HLAG. The method was tested again by immunofluorescence labeling
with antibody against beta-HCG using cells that were recovered by
immunomagnetic separation. Only human trophoblast cells express beta-hCG
and should have bind the antibody. This experiment allowed the establishment
of whether or not embryonic cells could be separated from maternal cells within
an actual cervical sample and determined the purity and recovery (both in terms
of percentage) of the HLAG positive cells when compared to the expected ratio.
In preliminary studies, cervical samples collected from pregnant patients between
weeks 7-10 were analyzed by beta-hCG immunofluorescence.

A majority of

trophoblast cells were recovered, and beta-hCG testing was 100% positive (as
shown by the table below) proving that the cells recovered were indeed
uncontaminated and HLAG positive.

Table 1.

Trophoblast isolation from cervical specimens.

Two specimens collected from pregnant

patients between Weeks 7-10 were analyzed by immunohistochemistry to determine trophoblast frequency
(HLA-G+ :Total cells) and predict the number of trophoblast cells expected from the total number used.
Approximately 10% of the specimens were processed by immunomagnetic affinity isolation to purify
trophoblast cells. Isolated cells were counted for comparison with the number of trophoblast cells expected.
Aliquots of the separated Bound cells and Non-bound cells from Samples# 8.4 and 8.25 were labeled with
anti-β-hCG to determine the percentage of cells expressing the trophoblast-specific protein in each group.

No.
No.
Sample

Trophoblast

Cells

No. Cells

ID

Frequency

Process

Expected

Trophobla

β-hCG +
β-hCG +

Cells

st

Non-Bound
Bound Cells

Isolated

Recovery

Cells

ed
8.4

1:1446

500,000

346

365

105%

100%

0%

8.25

1:1860

240,000

129

78

60%

100%

0%
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MATERIALS AND METHODS

Separating cells based on an embryo-specific marker.
A human trophoblast cell line (HTR) was used to demonstrate that it is possible
to isolate cells expressing an embryo-specific protein from a solution containing
an excess of cells lacking that protein. The HTR cell line was cultured using two
different methods. The HTR cell line was cultured on fibronectin and matrigel,
respectively, both basement membranes. Fibronectin does not affect the HTR
cells, while Matrigel forces them to express HLAG (human leukocyte antigen G),
which is only expressed by embryonic cells. Cervical specimens collected from
pregnant women during the first trimester contain both maternal (cervical) and
embryonic (trophoblast) cells. Thus, a mock cervical specimen was created as
represented by the HLAG positive and HLAG negative trophoblast cells. After
the cells were cultured, the cells were fixed and permeabilized.

The HLAG

positive cells were then stained with propidium iodide, a fluorescent red nuclear
stain.

The HLAG negative cells were stained with DAPI, a fluorescent blue

nuclear stain. The cells were then be counted and mixed together in a 1:2000
HLAG positive to negative ratio.

This ratio is consistent with the ratio of

embryonic cells to maternal cells that are collected from cervical samples (Imudia
et al., 2009). Once the cells were combined, they were separated based on their
expression of HLAG. The mixture of cells was incubated with magnetic beads
that had HLAG antibody coupled to their surface. Thus, all of the HLAG positive
cells were bound to the magnetic beads, and the HLAG negative cells remained
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free of beads. The cell mixture was then magnetized, the idea being that all of
the bead-bound cells should be attracted towards the magnet. By discarding the
supernatant and sufficiently washing the cells bound to the magnet, it became
possible to obtain a pure sample of HLAG positive cells. The success of this
separation was determined by fluorescence microscopy, which identified cells
labeled with propidium iodide or DAPI. If only a red fluorescent stain was visible,
that meant the HLAG positive cells were pure. A blue fluorescent stain should
not have been visible, as it would indicate that the isolated cells were impure.
After undergoing this experiment, it was determined that the separation was
indeed pure. This experiment established that embryonic cells could be
separated from maternal cells based on HLAG expression. The purity and
recovery (both in terms of percentage) of the HLAG positive cells was also
determined by this experiment. In preliminary studies, this approach was used
with a total of 100,000 cells containing 50 HLAG positive cells, and was able to
recover approximately 10-20% of the HLAG positive cells free of contaminating
HLAG negative cells. Recovery was not increased, and it was determined at a
later point that this was because cells induced to express HLAG slowly and
steadily lost their HLAG expression. When the experiment was repeated using
trophoblast cells derived from transcervical specimens, recovery peaked at 95100%.
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X and Y chromosome assessment of isolated cells and preliminary
experiments using HTR and fibroblast cells to refine method of PCR and
storage.
Since the method being developed revolved around using a single-cell approach
to conduct genetic testing, single-cell PCR was the first technique to be refined.
Cells were diluted down until very low concentrations of cells or single cells were
present in small volumes of RNase free water. Cells were then heated to boiling
point in a PCR tube with RNase free water using a heating block, which lysed the
cells to release the genomic DNA. Immunomagnetically isolated cells from these
samples were used to conduct single cell assays by amplifying sequences in
genes on the X (DMD) and Y (SRY) chromosomes by multiplex polymerase
chain reaction (PCR). Preliminary steps have been taken and correct amplified
products can be seen from single-cell PCR. Single bands were visible at the site
of the X amplicon for HTR cells, which are female.

The fibroblast cell line,

derived from human foreskin, generated two bands representing both X and Y
amplicons. This experiment ensured accurate results through PCR. Thus, when
immunomagnetically isolated cells from 20 patient specimens were used to
determine fetal gender in single cell assays, in the 270 total cells, PCR products
were detected in 256 (95%) and identified gender (11 male; 9 female) without
error. It was also vital to determine how the cervical samples would be stored
before PCR is conducted. Time trials with single cells from the cell lines were
conducted to see if PCR needed to be conducted immediately after cervical
samples are received or whether the cells from the samples could be isolated

Bajpayee 9	
  
and stored frozen before conducting PCR. Based on the PCR results, it was
determined that storage time did not affect results drastically. Thus, cervical
samples were allowed to be frozen before undergoing PCR.

Genetic assessment of DNA using a single-cell approach.
Genetic assessment of DNA was conducted using the HTR and fetal fibroblast
cell lines. Once the genetic assessment of DNA was completed using these
mock cells, the refined procedure was to work with transcervically derived
trophoblast cells. Because the maternal and embryonic cells in a cervical sample
cannot be differentially labeled before the cell separation procedure, the isolation
of pure trophoblast cells was further assessed (after completing beta-hCG
testing) by DNA fingerprinting. Preliminary experiments were carried out to
optimize DNA analysis protocols before proceeding with pilot cell separation
experiment using HLAG positive HTR cells and a genetically distinct HLAG
negative cell line. Cells in small groups or single cells were lysed for genomic
DNA isolation and amplification through heating, as there is no commercial kit
available at the time being that works with such low numbers of cells (similar to
what was done with single-cell PCR). The cells were placed in RNase free water
then boiled in order to lyse the cells and release the genetic content. Cells were
lysed for genomic DNA isolation and amplification with the Whole Genome
Amplification (WGA) Kit (Sigma Aldrich, St. Louis, MO) or Rubicon PicoPlexTM
WGA

(Rubican,

Ann

Arbor,

MI),

calculating

yields

by

Nanodrop

spectrophotometry (Wilmington, DE). DNA was isolated from each cell line to
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establish their DNA fingerprints.

Next, the whole genome amplification

procedure was piloted with decreasing numbers of cells, down to single cells,
followed by DNA fingerprinting.

DNA was then fingerprinted using the

AmpFlSTR Identifiler PCR Amplification kit (ABI) that was developed in
accordance with forensic standards (Collins et al., 2004). As two different cell
lines were used initially, the DNA fingerprints should have been different. If the
fingerprints were consistent and differed between cell lines, the testing could be
progressed from cell lines to transcervical samples. In this experiment reference
fingerprints needed to be obtained that would serve as a model for distinguishing
DNA from the cells. It was also important to acquire the ability to perform this
procedure with the small number of cells isolated in the cell separation procedure
used with cervical specimens. Despite diligent efforts, this method has not yet
become feasible for a single-cell approach. The method was however successful
on as little as 40 cells, which is substantially lower than the average of range of
thousands of cells that are normally required for this procedure.

RESULTS
Twenty-six transcervical specimens were obtained from pregnant women with
fetuses ranging in gestational age between 5 and 18 weeks (Table 2). Cell
counts suggested that trophoblast recovery after immunomagnetic isolation
averaged 101%. The average percentage of cells expressing β-CG among the
magnetically bound cells was 99% (range, 95%-100%; Table 2), while none of
the cells in the excluded, non-bound fraction were β-CG positive. To further
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establish that the isolated cells were trophoblast, immunofluorescence
microscopy was used to examine expression of marker proteins, β-CG, as
expressed by immunomagnetically isolated cells from transcervical specimens.

Table 2. Trophoblast Content, Recovery and Purity. TCS specimens obtained
from patients at the indicated gestational ages were examined by IHC for the
presence of HLA-G and the total number of HLA-G-positive cells in each
specimen was estimated. Anti-HLA-G-binding cells were isolated with magnetic
nanoparticles and the total number of cells recovered from each specimen was
estimated from cell counts, with the percentage of that predicted by IHC shown in
parentheses. Immunofluorescence microscopy was used to determine the
number of cells expressing β-CG/total cells examined, with the percentage
expressing β-CG shown in parentheses.
	
  

Gestational	
  Age	
  
#	
  HLA-‐G-‐
(weeks.days)	
  
Positive	
  Cells	
  
5.3
1313
6
609
7
575
7.3
677
7.4
842
7.5
314
7.6
1108
8
593
8
1045
8
609
8
788
9.2
1260
10
2222
10
1095
11
581
11
1027
11
529
12
850
12
879
12.4
1109
14
820

#	
  Isolated	
  Cells	
  
(%	
  Recovered)	
  	
  
1140 (87)
998 (164)
593 (103)
855 (126)
623 (74)
870 (277)
345 (31)
510 (86)
728 (70)
660 (108)
848 (108)
248 (20)
1462 (66)
1020 (93)
720 (124)
622 (61)
1463 (277)
578 (68)
758 (86)
495 (45)
705 (86)

β-‐CG	
  Reactive	
  (%)	
  
	
  
233/233 (100)
190/200 (95)
118/118 (100)
540/542 (99.6)
100/102 (98)
250/250 (100)
1482/1500(98.8)
250//250 (100)
93/94 (98.9)
58/58 (100)
69/70 (99)
1485/1500 (99)
793/811 (97.8)
84/84 (100)
594/598 (99.3)
250/250 (100)
181/191 (98.4)
247/250 (98.9)
96/96 (100)
53/55 (96.4)
87/87 (100)
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Average

14.6
15.2
15.4
17.5
17.6
10.4

466
570
2467
1009
239
908

660 (142)
570 (100)
832 (34)
818 (81)
270 (113)
746 (101)

1485/1500 (99)
385/387 (99.5)
992/1000 (99.2)
850/853 (99.6)
966/970 (99.6)
99%

To establish that trophoblast cells isolated from transcervical specimens were a
valid source of fetal DNA for single cell prenatal genetic diagnosis, multiplex PCR
was conducted with replicates of individual frozen cells from 20 patient specimen
using primers for DMD and SRY to detect the presence of an X (control) or Y
chromosome, respectively. Male fetuses were readily identified by amplification
of two bands, while trophoblast cells from female fetuses produced only the X
band. In addition to individual trophoblast cells, PCR analysis of each specimen
included single foreskin fibroblasts or isolated foreskin DNA as positive male
controls. The fetal sex of all 20 pregnancies was correctly determined, as verified
by delivery records (Table 3). There were nine female and eleven male fetuses
among the twenty specimens examined. The specificity of the PCR worked well,
as SRY amplicons were clearly distinguished from DMD amplicons. Overall,
there were no visible bands produced by PCR in 14 of 270 cells evaluated
(5.2%). The PCR-determined genders of individual cells were homogeneous
within every specimen.

Table 3. Fetal Gender Determination. Anti-HLA-G-bound cells isolated with
magnetic nanoparticles were assayed by single cell, multiplex PCR for the X and
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Y chromosome markers DMD and SRY, respectively. Five to thirty replicate
cells from each patient were examined to determine the presence or absence of
each chromosome, presented as the number of cells that produced an
amplicon/total cells examined. Genders were verified from birth records.
Gestational	
  Age	
  
(weeks.days)	
  

X	
  Chromosome	
  
detected	
  (%)	
  

Y	
  Chromosome	
  
detected	
  (%)	
  

Gender	
  
Verification	
  

5.3
6
7.6
8
10
12
12
12.4
17.6
7.3
7.5
8
9.2
10
11
12
14
14.6
15.2
17.5

10/10 (100)
25/30 (83.3)
25/25 (100)
10/10 (100)
10/10 (100)
10/10 (100)
9/10 (90)
10/10 (100)
10/10 (100)
5/5 (100)
10/10 (100)
25/28 (89.3)
10/10 (100)
10/10 (100)
10/10 (100)
24/26 (92.3)
6/6 (100)
18/20 (90)
9/10 (90)
10/10 (100)

0/10 (0)
0/30 (0)
0/25 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
5/5 (100)
10/10 (100)
25/28 (89.3)
10/10 (100)
10/10 (100)
10/10 (100)
24/26 (92.3)
6/6 (100)
18/20 (90)
9/10 (90)
10/10 (100)

Female
Female
Female
Female
Female
Female
Female
Female
Female
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male

FUTURE DIRECTIONS
This method was implemented in all experiments, especially when cervical cell
samples from pregnant patients obtained by physicians in the Department of
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Obstetrics & Gynecology were used. If fingerprinting can be refined for use with
a single-cell, then it will be establish whether the isolated cells are free of
maternal DNA, which can easily be determined with a blood sample from the
mother. It should be noted, however, that purity of the fetal cells may eventually
become less important than yield.

New technologies are currently being

developed that use bioinformatics to distinguish maternal from fetal sequence
information (Chiu et al., 2008; Jorgez and Bischoff, 2009; Lo et al., 2007; Lun et
al., 2008).

By completing this study with the use of cervical cell samples from pregnant
patients that were obtained by physicians in the Department of Obstetrics &
Gynecology, the non-invasive alternative technique to amniocentesis and CVS
was further developed. Fingerprinting will help establish whether the isolated
cells are free of maternal DNA, which can easily be determined with a blood
sample from the mother. With the culmination of this project, there is the hope
that the investigated non-invasive method will eventually lead to clinical trials.
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